A Phase 3 interventional study of Olaparib and Paclitaxel in Gastric Cancer, sponsored by AstraZeneca. Completed at 57 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-03-22.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Stomach Neoplasms by AstraZeneca — 10 open to participants now, 18 under way, 3 of them phase 3. Stomach Neoplasms · AstraZeneca.
Among the 30 studies in Stomach Neoplasms by AstraZeneca, this one is the 6th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 3, and was the 7th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →10 of the 30 studies in Stomach Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Greece
Ages 18–130
AstraZeneca · Sites in United States, Australia, Austria and 21 more countries
Ages 18+
AstraZeneca · Sites in United States, Australia, Japan and 1 more country
Ages 18+
AstraZeneca · Sites in United States, Canada, China and 8 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
By country, each count listing its studies:
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 16 · Phase 3 4
First in 2007; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 525 is above the median of 66 across 2,500 interventional studies indexed under Stomach Neoplasms.
Median enrollment 124 across the 27 interventional studies, 300 across the 3 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
8 of the studies in Stomach Neoplasms by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06219941AstraZenecaAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | 2026-11-17 |
| NCT06147037AstraZenecaA Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | 2026-12-31 |
| NCT06921928AstraZenecaStudy for AZD4360 in Participants With Advanced Solid Tumours | 2027-03-31 |
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
| NCT04644068AstraZenecaStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | 2027-05-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 30 studies in Stomach Neoplasms by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy. Patients will be from China, Japan , Korea and Taiwan.
A randomized, double-blinded, multicentre phase III study to access the efficacy and safety of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in Asian patients with advanced gastric cancer (including gastro-oesophageal junction) who have progressed following first line therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
olaparib + paclitaxel
Drug: Olaparib · Drug: Paclitaxel
placebo+ paclitaxel
Drug: Paclitaxel · Drug: Placebo
Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
Overall Survival
Time from the date of randomization until death due to any cause
Time frame: Survival contact from the date of randomization and then every 8 weeks following objective disease progression and in the 7 days following OS Data Cut off (DCO); Time point(s) at which outcome measure is assessed up to 4 years
Progression-Free Survival (PFS)
Time from randomization until the date of objective radiological disease progression according to RECIST (v1.1) or death by any cause in the absence of progression. Objective progression is defined as at least a 20% increase in the sum of the diameters of the target lesions (compared to previous minimum sum) or an overall non-target lesion assessment of progression or a new lesion.
Time frame: Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Number of Patients With Objective Response.
Number of patients with objective response. Per RECIST 1.1, complete response (CR) is disappearance of all target lesions since baseline; partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Overall Response = CR + PR.
Time frame: Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Number of Patients Objective Response
Number of patients with objective response. Per RECIST 1.1, complete response (CR) is disappearance of all target lesions since baseline; partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Overall Response = CR + PR.
Time frame: Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Number of Patients With Deterioration of Health Related Quality of Life (HRQoL) as Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 Item Module (QLQ-C30) Global HRQoL Scale
Number of patients with a clinically important deterioration in the global HRQoL score or death by any cause in the absence of a clincially meaningful symptom deterioration
Time frame: Pre-treatment , Day 29 and then every 4 weeks until discontinuation, assessed up to 3 years
Time to Response
Time from randomization to the first onset of a confirmed objective tumour response
Time frame: Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
Duration of Response
Time from the first documentation of CR/PR until the date of progression, or the last evaluable RECIST assessment for patients taht do not progress or progress after two or more missed visits
Time frame: Scans taken at baseline and then follow up assessments taken every 8 weeks up to Week 40 and then every 16 weeks until objective disease progression as defined by RECIST 1.1, assessed up to 3 years
| Milestone | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Started | 263 | 262 |
| Completed | 74 | 57 |
| Not completed | 189 | 205 |
| Withdrew: Death | 181 | 200 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 7 | 3 |
| Withdrew: Other eligibility criteria | 1 | 1 |
Time from the date of randomization until death due to any cause
| participants | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Overall Survival | 82 | 62 |
Time from the date of randomization until death due to any cause
| participants | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Overall Survival | 19 | 11 |
Time from randomization until the date of objective radiological disease progression according to RECIST (v1.1) or death by any cause in the absence of progression. Objective progression is defined as at least a 20% increase in the sum of the diameters of the target lesions (compared to previous minimum sum) or an overall non-target lesion assessment of progression or a new lesion.
| participants | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Progression-Free Survival (PFS) | 47 | 29 |
Time from randomization until the date of objective radiological disease progression according to RECIST (v1.1) or death by any cause in the absence of progression. Objective progression is defined as at least a 20% increase in the sum of the diameters of the target lesions (compared to previous minimum sum) or an overall non-target lesion assessment of progression or a new lesion.
| participants | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Progression-Free Survival (PFS) | 11 | 7 |
Number of patients with objective response. Per RECIST 1.1, complete response (CR) is disappearance of all target lesions since baseline; partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Overall Response = CR + PR.
| participants | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Number of Patients With Objective Response. | 44 | 28 |
Number of patients with objective response. Per RECIST 1.1, complete response (CR) is disappearance of all target lesions since baseline; partial response (PR) is at least a 30% decrease in the sum of the diameters of target lesions. Overall Response = CR + PR.
| participants | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Number of Patients Objective Response | 12 | 5 |
Number of patients with a clinically important deterioration in the global HRQoL score or death by any cause in the absence of a clincially meaningful symptom deterioration
| participants | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Number of Patients With Deterioration of Health Related Quality of Life (HRQoL) as Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 Item Module (QLQ-C30) Global HRQoL Scale | 160 | 177 |
Number of patients with a clinically important deterioration in the global HRQoL score or death by any cause in the absence of a clincially meaningful symptom deterioration
| participants | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Number of Patients With Deterioration of Health Related Quality of Life (HRQoL) as Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Questionnaire Core 30 Item Module (QLQ-C30) Global HRQoL Scale | 29 | 33 |
Time from randomization to the first onset of a confirmed objective tumour response
| days | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Time to Response | 57.0 (54.5 to 64.0) | 57.0 (56.0 to 111.5) |
Time from randomization to the first onset of a confirmed objective tumour response
| days | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Time to Response | 57.5 (57.0 to 113.0) | 57.0 (55.0 to 58.0) |
Time from the first documentation of CR/PR until the date of progression, or the last evaluable RECIST assessment for patients taht do not progress or progress after two or more missed visits
| days | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Duration of Response | 166.0 (89.0 to 218.0) | 64.0 (54.0 to 186.0) |
Time from the first documentation of CR/PR until the date of progression, or the last evaluable RECIST assessment for patients taht do not progress or progress after two or more missed visits
| days | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Duration of Response | 171.0 (124.0 to 350.0) | 108.0 (57.0 to 113.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | 181/263 (68.8%) | 92/262 (35.1%) | 257/262 (98.1%) |
| Placebo Tablets bd + Paclitaxel 80 mg/m^2 | 200/262 (76.3%) | 65/259 (25.1%) | 253/259 (97.7%) |
| Event | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| Bone marrow disorderBlood and lymphatic system disorders | 6/262 | 3/259 |
| PneumoniaInfections and infestations | 6/262 | 4/259 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/262 | 2/259 |
| GranulocytopeniaBlood and lymphatic system disorders | 5/262 | 2/259 |
| LeukopeniaBlood and lymphatic system disorders | 5/262 | 0/259 |
| IleusGastrointestinal disorders | 4/262 | 4/259 |
| VomitingGastrointestinal disorders | 4/262 | 4/259 |
| PyrexiaGeneral disorders | 4/262 | 4/259 |
| Abdominal painGastrointestinal disorders | 4/262 | 3/259 |
| Intestinal obstructionGastrointestinal disorders | 3/262 | 1/259 |
| Event | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 122/262 | 108/259 |
| AlopeciaSkin and subcutaneous tissue disorders | 112/262 | 116/259 |
| AnaemiaBlood and lymphatic system disorders | 99/262 | 62/259 |
| Decreased appetiteMetabolism and nutrition disorders | 86/262 | 69/259 |
| NauseaGastrointestinal disorders | 75/262 | 63/259 |
| LeukopeniaBlood and lymphatic system disorders | 71/262 | 57/259 |
| Neutrophil count decreasedInvestigations | 67/262 | 38/259 |
| DiarrhoeaGastrointestinal disorders | 66/262 | 51/259 |
| White blood cell count decreasedInvestigations | 60/262 | 48/259 |
| FatigueGeneral disorders | 48/262 | 52/259 |
| Age, Continuous(Years) | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| Mean | 57.1 ± 11.90 | 57.3 ± 11.14 | 57.2 ± 11.52 |
| Age, Continuous(Years) | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| Mean | 57.0 ± 12.08 | 60.9 ± 9.90 | 58.9 ± 11.18 |
| Age, Customized(Participants) | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| >=18 - <50 | 68 | 64 | 132 |
| >=50 - <65 | 115 | 128 | 243 |
| >=65 | 80 | 70 | 150 |
| Age, Customized(Participants) | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| >=18 - <50 | 12 | 7 | 19 |
| >=50 - <65 | 22 | 24 | 46 |
| >=65 | 14 | 15 | 29 |
| Sex: Female, Male(Participants) | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| Female | 89 | 77 | 166 |
| Male | 174 | 185 | 359 |
| Race/Ethnicity, Customized(Participants) | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| Not Hispanic Or Latino | 263 | 262 | 525 |
| Race/Ethnicity, Customized(Participants) | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| Asian | 263 | 262 | 525 |
| Race/Ethnicity, Customized(Participants) | Olaparib 100 mg Tablets bd + Paclitaxel 80 mg/m^2 | Placebo Tablets bd + Paclitaxel 80 mg/m^2 | Total |
|---|---|---|---|
| Not Hispanic or Latino | 48 | 46 | 94 |
4 further baseline measures are reported on the registry.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Sep 2013 to primary completion in Apr 2016, 31 months.
Results were first posted in Nov 2018, 2 years 7 months after primary completion.
Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 31 months is below that.
Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib